Attovia Therapeutics has accreted a hefty $289 million from its IPO to power its anti-itch drugs through clinical development, marking another upsized listing in what has become a banner year for biotech Nasdaq debuts.
Attovia’s CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
Post navigation
Previous Post
Yao Earns Prestigious NSF CAREER Award